Overview
NanoMab is developing next generation radiopharmaceuticals for cancer precision medicine to be used in conjunction with the established global network of PET facilities. Our goal is to develop a pipeline of theranostic couple camelid antibodies with our proprietary camelid antibodies platform to address the unmet diagnostic and medical need for cancer patients in the world.